# Ceptaris Therapeutics, Inc.,

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ceptaris-therapeutics-inc

- Industry: Pharmaceuticals
- Headquarters: Malvern, US
- Website: www.ceptaris.com
- Total disclosed funding: $30M
- Latest round: Series D (May 14, 2012)
- Investors on record: 9

## About

Founded in 2002 and based in Malvern, United States, Ceptaris Therapeutics, Inc., formerly known as Yaupon Therapeutics Inc. is a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.

## Funding rounds

- Series D, May 14, 2012, $8.3M — Burrill & Company, Aperture Venture Partners, Vivo Capital, Third Point, Palo Alto Investors, BioAdvance, Osage Venture Partners
- Series D, Aug 11, 2011, $14M — Burrill & Company, Aperture Venture Partners, Vivo Capital, Palo Alto Investors
- Series C, Aug 17, 2009, $3.1M — Vivo Capital, Osage Venture Partners
- Series B, Nov 13, 2006, $4M — TDH Private Equity Management Company, Ben Franklin Technology Partners, BioAdvance, Osage Venture Partners

## Investors

- TDH Private Equity Management Company (https://capitalatlas.ai/funds/tdh-private-equity-management-company) — Series B
- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Series B
- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Series B, Series D
- Osage Venture Partners (https://capitalatlas.ai/funds/osage-venture-partners) — Series B, Series C, Series D
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C, Series D
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series D
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series D
- Palo Alto Investors (https://capitalatlas.ai/funds/palo-alto-investors) — Series D
- Third Point (https://capitalatlas.ai/funds/third-point) — Series D